Literature DB >> 21633639

Protective effects of ACLF sera on metabolic functions and proliferation of hepatocytes co-cultured with bone marrow MSCs in vitro.

Xiao-Lei Shi1, Jin-Yang Gu, Yue Zhang, Bing Han, Jiang-Qiang Xiao, Xian-Wen Yuan, Ning Zhang, Yi-Tao Ding.   

Abstract

AIM: To investigate whether the function of hepatocytes co-cultured with bone marrow mesenchymal stem cells (MSCs) could be maintained in serum from acute-on-chronic liver failure (ACLF) patients.
METHODS: Hepatocyte supportive functions and cytotoxicity of sera from 18 patients with viral hepatitis B-induced ACLF and 18 healthy volunteers were evaluated for porcine hepatocytes co-cultured with MSCs and hepatocyte mono-layered culture, respectively. Chemokine profile was also examined for the normal serum and liver failure serum.
RESULTS: Hepatocyte growth factor (HGF) and Tumor necrosis factor; tumor necrosis factor (TNF)-α were remarkably elevated in response to ACLF while epidermal growth factor (EGF) and VEGF levels were significantly decreased. Liver failure serum samples induced a higher detachment rate, lower viability and decreased liver support functions in the homo-hepatocyte culture. Hepatocytes co-cultured with MSCs could tolerate the cytotoxicity of the serum from ACLF patients and had similar liver support functions compared with the hepatocytes cultured with healthy human serum in vitro. In addition, co-cultured hepatocytes maintained a proliferative capability despite of the insult from liver failure serum.
CONCLUSION: ACLF serum does not impair the cell morphology, viability, proliferation and overall metabolic capacities of hepatocyte co-cultured with MSCs in vitro.

Entities:  

Keywords:  Acute-on-chronic liver failure serum; Bone marrow marrow mesenchymal stem cells; Co-culture; Hepatocyte-based modality; Primary hepatocytes

Mesh:

Substances:

Year:  2011        PMID: 21633639      PMCID: PMC3103792          DOI: 10.3748/wjg.v17.i19.2397

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

Review 1.  Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review.

Authors:  Lise L Kjaergard; Jianping Liu; Bodil Als-Nielsen; Christian Gluud
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

2.  Serum from patients with fulminant hepatic failure causes hepatocyte detachment and apoptosis by a beta(1)-integrin pathway.

Authors:  Philip N Newsome; John Tsiaoussis; Steven Masson; Robert Buttery; Cameron Livingston; Ian Ansell; James A Ross; Tariq Sethi; Peter C Hayes; John N Plevris
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

3.  Engineering micropatterned surfaces for the coculture of hepatocytes and Kupffer cells.

Authors:  Yekaterina S Zinchenko; Robin N Coger
Journal:  J Biomed Mater Res A       Date:  2005-10-01       Impact factor: 4.396

4.  Effects of plasma from patients with fulminant hepatic failure on function of primary rat hepatocytes in three-dimensional culture.

Authors:  Masahito Nagaki; Tomoo Naito; Hiroo Ohnishi; Toshihiro Akaike; Yasutoshi Muto; Hisataka Moriwaki
Journal:  Liver Int       Date:  2005-10       Impact factor: 5.828

5.  Interleukin 18 and hepatocyte growth factor in fulminant hepatic failure of adult onset Still's disease.

Authors:  Atsushi Ogata; Masayasu Kitano; Jyunichi Yamanaka; Tomoko Yamasaki; Naoaki Hashimoto; Tsuyoshi Iwasaki; Teruaki Hamano; Jiro Fujimoto; Eizo Kakishita
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

6.  Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.

Authors:  Yong Yuan; Uchenna Iloeje; Hong Li; Joel Hay; Guang B Yao
Journal:  Value Health       Date:  2008-03       Impact factor: 5.725

7.  Functional assessment of the quality of human hepatocyte preparations for cell transplantation.

Authors:  María Teresa Donato; Agustín Lahoz; Sandra Montero; Ana Bonora; Eugenia Pareja; José Mir; José V Castell; María José Gómez-Lechón
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

8.  Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver.

Authors:  Paul P C Poyck; Albert C W A van Wijk; Tessa V van der Hoeven; Dirk R de Waart; Robert A F M Chamuleau; Thomas M van Gulik; Ronald P J Oude Elferink; Ruurdtje Hoekstra
Journal:  J Hepatol       Date:  2007-12-17       Impact factor: 25.083

9.  Clinical applications of hepatocyte transplantation.

Authors:  Giada Pietrosi; Giovanni Battista Vizzini; Salvatore Gruttadauria; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

10.  In vitro effects of sera from children with acute liver failure on metabolic and synthetic activity of cryopreserved human hepatocytes.

Authors:  Ragai R Mitry; Sanjay Bansal; Robin D Hughes; Giorgina Mieli-Vergani; Anil Dhawan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-05       Impact factor: 2.839

View more
  3 in total

1.  VEGF(165) expressing bone marrow mesenchymal stem cells differentiate into hepatocytes under HGF and EGF induction in vitro.

Authors:  Yan Tan; En-Hua Xiao; Li-Zhi Xiao; You-Hong Yuan; Cong Ma; Quan-Liang Shang; Du-Jun Bian; Yan-Hui Li; Zhu Chen; Qian Chang
Journal:  Cytotechnology       Date:  2012-04-04       Impact factor: 2.058

2.  Evaluation of a novel hybrid bioartificial liver based on a multi-layer flat-plate bioreactor.

Authors:  Xiao-Lei Shi; Yue Zhang; Xue-Hui Chu; Bing Han; Jin-Yang Gu; Jiang-Qiang Xiao; Jia-Jun Tan; Zhong-Ze Gu; Hao-Zhen Ren; Xian-Wen Yuan; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

3.  Hypoxic preconditioning potentiates the trophic effects of mesenchymal stem cells on co-cultured human primary hepatocytes.

Authors:  Harry H Qin; Céline Filippi; Song Sun; Sharon Lehec; Anil Dhawan; Robin D Hughes
Journal:  Stem Cell Res Ther       Date:  2015-12-01       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.